Literature DB >> 25936722

Characterization of a novel oil-in-water emulsion adjuvant for swine influenza virus and Mycoplasma hyopneumoniae vaccines.

A Galliher-Beckley1, L K Pappan1, Rachel Madera1, Y Burakova2, A Waters1, M Nickles1, X Li1, J Nietfeld3, J R Schlup4, Q Zhong5, S McVey6, S S Dritz3, J Shi7.   

Abstract

Vaccines consisting of subunit or inactivated bacteria/virus and potent adjuvants are widely used to control and prevent infectious diseases. Because inactivated and subunit antigens are often less antigenic than live microbes, a growing need exists for the development of new and improved vaccine adjuvants that can elicit rapid and long-lasting immunity. Here we describe the development and characterization of a novel oil-in-water emulsion, OW-14. OW-14 contains low-cost plant-based emulsifiers and was added to antigen at a ratio of 1:3 with simple hand mixing. OW-14 was stable for prolonged periods of time at temperatures ranging from 4 to 40°C and could be sterilized by autoclaving. Our results showed that OW-14 adjuvanted inactivated swine influenza viruses (SIV; H3N2 and H1N1) and Mycoplasma hyopneumoniae (M. hyo) vaccines could be safely administered to piglets in two doses, three weeks apart. Injection sites were monitored and no adverse reactions were observed. Vaccinated pigs developed high and prolonged antibody titers to both SIV and M. hyo. Interestingly, antibody titers were either comparable or greater than those produced by commercially available FluSure (SIV) or RespiSure (M. hyo) vaccines. We also found that OW-14 can induce high antibody responses in pigs that were vaccinated with a decreased antigen dose. This study provides direct evidence that we have developed an easy-to-use and low-cost emulsion that can act as a powerful adjuvant in two common types of swine vaccines.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Adjuvant; Mycoplasma; Oil-in-water emulsion; Swine influenza virus; Vaccine

Mesh:

Substances:

Year:  2015        PMID: 25936722     DOI: 10.1016/j.vaccine.2015.04.065

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice.

Authors:  Weiping Cao; William G Davis; Jin Hyang Kim; Juan A De La Cruz; Andrew Taylor; Grant R Hendrickson; Amrita Kumar; Priya Ranjan; L Andrew Lyon; Jacqueline M Katz; Shivaprakash Gangappa; Suryaprakash Sambhara
Journal:  Nanomedicine       Date:  2016-04-23       Impact factor: 5.307

2.  Comparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses.

Authors:  Eugenio J Abente; Daniela S Rajao; Jefferson Santos; Bryan S Kaplan; Tracy L Nicholson; Susan L Brockmeier; Phillip C Gauger; Daniel R Perez; Amy L Vincent
Journal:  J Virol       Date:  2018-10-29       Impact factor: 5.103

3.  Efficacy comparison of commercial porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae monovalent and bivalent vaccines against a dual challenge.

Authors:  Siyeon Yang; Su-Jin Park; Taehwan Oh; Hyejean Cho; Chanhee Chae
Journal:  Can J Vet Res       Date:  2020-10       Impact factor: 1.310

4.  Assessment of the adjuvant activity of mesoporous silica nanoparticles in recombinant Mycoplasma hyopneumoniae antigen vaccines.

Authors:  Veridiana Gomes Virginio; Natalia Costantin Bandeira; Fernanda Munhoz Dos Anjos Leal; Marcelo Lancellotti; Arnaldo Zaha; Henrique Bunselmeyer Ferreira
Journal:  Heliyon       Date:  2017-01-06

5.  Toward the development of a one-dose classical swine fever subunit vaccine: antigen titration, immunity onset, and duration of immunity.

Authors:  Rachel F Madera; Lihua Wang; Wenjie Gong; Yulia Burakova; Sterling Buist; Jerome Nietfeld; Jamie Henningson; Ada G Cino-Ozuna; Changchun Tu; Jishu Shi
Journal:  J Vet Sci       Date:  2018-05-31       Impact factor: 1.672

6.  Systems Immunology Characterization of Novel Vaccine Formulations for Mycoplasma hyopneumoniae Bacterins.

Authors:  Anneleen M F Matthijs; Gaël Auray; Virginie Jakob; Obdulio García-Nicolás; Roman O Braun; Irene Keller; Rémy Bruggman; Bert Devriendt; Filip Boyen; Carlos A Guzman; Annelies Michiels; Freddy Haesebrouck; Nicolas Collin; Christophe Barnier-Quer; Dominiek Maes; Artur Summerfield
Journal:  Front Immunol       Date:  2019-05-24       Impact factor: 7.561

7.  Injectable Excipients as Novel Influenza Vaccine Adjuvants.

Authors:  Huapeng Feng; Makoto Yamashita; Tiago Jose da Silva Lopes; Tokiko Watanabe; Yoshihiro Kawaoka
Journal:  Front Microbiol       Date:  2019-01-24       Impact factor: 5.640

8.  Comparative Evaluation of Growth Performance between Bivalent and Trivalent Vaccines Containing Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae in a Herd with Subclinical PCV2d Infection and Enzootic Pneumonia.

Authors:  Hyungmin Um; Siyeon Yang; Taehwan Oh; Keehwan Park; Hyejean Cho; Jeongmin Suh; Kyung-Duk Min; Chanhee Chae
Journal:  Vaccines (Basel)       Date:  2021-05-03

9.  Pigs immunized with a novel E2 subunit vaccine are protected from subgenotype heterologous classical swine fever virus challenge.

Authors:  Rachel Madera; Wenjie Gong; Lihua Wang; Yulia Burakova; Karen Lleellish; Amy Galliher-Beckley; Jerome Nietfeld; Jamie Henningson; Kaimin Jia; Ping Li; Jianfa Bai; John Schlup; Scott McVey; Changchun Tu; Jishu Shi
Journal:  BMC Vet Res       Date:  2016-09-09       Impact factor: 2.741

10.  Plant-made E2 glycoprotein single-dose vaccine protects pigs against classical swine fever.

Authors:  Richard C Laughlin; Rachel Madera; Yair Peres; Brian R Berquist; Lihua Wang; Sterling Buist; Yulia Burakova; Sreenath Palle; Chungwon J Chung; Max V Rasmussen; Erica Martel; David A Brake; John G Neilan; Sara D Lawhon; L Garry Adams; Jishu Shi; Sylvain Marcel
Journal:  Plant Biotechnol J       Date:  2018-08-10       Impact factor: 9.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.